Voreloxin: Additional Phase II data

Additional data from the Phase II REVEAL-1 trial in 113 previously untreated patients showed that 72 mg/m 2 of IV voreloxin weekly for 3 weeks (n=29) produced a median overall survival (OS) of 8.7 mon...